Biology and genetics

Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw. Musolino C et al. Ann Hematol. 2018 Mar 15. doi: 10.1007/s00277-018-3296-7. [Epub ahead of print]. A novel nano-immunoassay method for quantification of proteins from CD138 purified myeloma cells: biological and clinical utility. Misiewicz-Krzeminska I et al. Haematologica. 2018 Mar 15. pii: haematol.2017.181628. doi: 10.3324/haematol.2017.181628. [Epub ahead…

Details
Journal, Library, Management of Myeloma

Ixazomib combination demonstrates efficacy in relapsed and refractory myeloma patients

Results from a Phase II study, recently published in Leukaemia, show that the oral combination of ixazomib (Ninlaro®), pomalidomide (Imnovid®) and dexamethasone is effective in relapsed and refractory myeloma patients. All patients in this study were refractory to lenalidomide (Revlimid®). 48% of patients who received the recommended dose of ixazomib (4mg) achieved a partial response or…

Details
News

Pomalidomide combination shows efficacy in relapsed and refractory myeloma patients with renal impairment

Published in the Journal of Clinical Oncology, results from the Phase II trial, MM-013 show that pomalidomide (Imnovid®) in combination with low-dose dexamethasone is effective in relapsed and refractory patients with renal impairment. There were 3 cohorts in this trial; patients with moderate renal impairment (A), severe renal impairment (B) and severe impairment requiring haemodialysis…

Details
News

Supportive treatments

Denosumab for myeloma bone disease: ready for prime time? Dimopoulos MA et al. Lancet Oncol. 2018 Feb 8. pii: S1470-2045(18)30075-5. doi: 10.1016/S1470-2045(18)30075-5. [Epub ahead of print]. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Raje N et al. Lancet Oncol. 2018 Feb 8. pii: S1470-2045(18)30072-X. doi: 10.1016/S1470-2045(18)30072-X. [Epub ahead of…

Details
Journal, Library, Myeloma Prognosis & Outcomes

General

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. Frerichs KA et al.Expert Rev Clin Immunol. 2018 Feb 21. doi: 10.1080/1744666X.2018.1443809. [Epub ahead of print]. Multinucleated giant myeloma cells after failure of daratumumab therapy. Guijarro F et al. Br J Haematol. 2018 Feb 22. doi: 10.1111/bjh.15139. [Epub ahead of print]. Defining a set of standardised outcome measures for newly diagnosed patients…

Details
Journal, Library

Emerging treatments

FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma. Pulte ED et al. Oncologist. 2018 Feb 7. pii: theoncologist.2017-0440. doi: 10.1634/theoncologist.2017-0440. [Epub ahead of print]. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. Richardson PG et al. Br J Haematol. 2018 Feb 13. doi: 10.1111/bjh.15058. [Epub…

Details
Journal, Library

Diagnostic techniques and prognostic indicators

Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma. Pan Y et al.Clin Chim Acta. 2018 Feb 19;480:199-205. doi: 10.1016/j.cca.2018.02.019. [Epub ahead of print]. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple MyelomaWith Deep Responses. Miyazaki K et al. Clin Lymphoma Myeloma Leuk. 2018 Feb 19. pii: S2152-2650(17)31288-0. doi: 10.1016/j.clml.2018.01.008.…

Details
Diagnosing and Monitoring Myeloma, Journal, Library

Current treatments

Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone. Tanimura A et al. Int J Hematol. 2018 Jan 31. doi: 10.1007/s12185-018-2408-4. [Epub ahead of print]. Phase 1/2 Trial of Carfilzomib Plus High Dose Melphalan Preparative Regimen for Salvage AHCT Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Costa LJ et al. Biol Blood…

Details
Journal

Complications of myeloma and its treatments

Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Shah C et al. Leuk Lymphoma. 2018 Feb 21:1-13. doi: 10.1080/10428194.2018.1437269. [Epub ahead of print]. Acquired factor V deficiency in a patient with myeloma and amyloidosis. Quek JKS et al. Thromb Res. 2018 Jan 31;164:1-3. doi: 10.1016/j.thromres.2018.01.045. [Epub ahead of print]. Community-acquired respiratory infections are common in patients with non-Hodgkin lymphoma and multiple myeloma. Lavi N et…

Details
Journal, Library, Management of complications & side effects